CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and ...

Indonesia has delayed plans to extract more revenue from the mining sector until it can figure out an "ideal formulation" ...

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued developmentCLYM116 modeling ...

Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May ...

Analyst/Investor Day May 11, 2026 10:00 AM EDTCompany ParticipantsSuann Guthrie - Senior Vice President of Investor ...

PRECISE-AD Phase 1b trial is fully enrolled and progressing on schedule, with the blinded 6-month interim analysis anticipated in early Q3 2026 and 12-month top-line data anticipated in early 2027. ...

Q1 2026 earnings call recap: 42% revenue growth, $1B buyback, reaffirmed 2026 guidance, and Hypercon Phase I timing shift.

Indonesia is targeting economic ​growth of between 5.9% and ‌7.5% in 2027, its planning minister said on Thursday, driven by ...

SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the third quarter of 2026; SCYNEXIS is accepting ...

The reduction of our net loss in 2025 from 2024 was primarily related to the LifeSci Capital LLC judgment expense and reimbursement of legal costs, clinical trial related settlement expenses with A-IR ...

Editor's note: This story is one in a series on the June 2 primary election. For more coverage, visit vcstar.com/news/elections. (This story was updated to include ...